Polycystic Kidney Disease-Pipeline Review, H1 2017

Polycystic Kidney Disease-Pipeline Review, H1 2017


  • Products Id :- GMDHC9241IDB
  • |
  • Pages: 84
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Polycystic Kidney Disease-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease-Pipeline Review, H1 2017, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Polycystic Kidney Disease-Overview

Polycystic Kidney Disease-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Polycystic Kidney Disease-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Polycystic Kidney Disease-Companies Involved in Therapeutics Development

3SBio Inc

Angion Biomedica Corp

Aptevo Therapeutics Inc

Conatus Pharmaceuticals Inc

DiscoveryBiomed Inc

Endocyte Inc

IC-MedTech Inc

Ipsen SA

Kadmon Corp LLC

ManRos Therapeutics

Metabolic Solutions Development Company LLC

Mironid Ltd

NovaTarg Therapeutics Inc

Otsuka Holdings Co Ltd

Q BioMed Inc

Regulus Therapeutics Inc

XORTX Pharma Corp

Polycystic Kidney Disease-Drug Profiles

(sodium ascorbate + menadione sodium bisulfite)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANG-3070-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIM-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CR-8-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBM-43H11-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DJ-5-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Cystic Kidney Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EC-0371-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDN-8050-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-153-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanreotide acetate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

menadione sodium bisulfite-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSDC-0160-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oxypurinol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrimethamine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RGLS-4326-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate AMPK for Polycystic Kidney Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PDE4 for Kidney Diseases-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

STA-2842-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesevatinib tosylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TNFR x TWEAKR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolvaptan-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Polycystic Kidney Disease-Dormant Projects

Polycystic Kidney Disease-Discontinued Products

Polycystic Kidney Disease-Product Development Milestones

Featured News & Press Releases

Mar 16, 2017: Otsuka Pharmaceutical Receives Approval for the Additional Formulation of Samsca Granules 1% in Japan

Feb 16, 2017: Regulus Announces Publication in Nature Communications Identifying miR-17 as a Promising Drug Target for ADPKD

Dec 06, 2016: Regulus Announces Update on RGLS4326

Nov 19, 2016: Kadmon to Present Additional Data Demonstrating Tesevatinib Safety for the Treatment of Polycystic Kidney Disease at ASN Kidney Week 2016

Jan 11, 2016: Scottish Medicines Consortium Issues Positive Advice For First Ever Treatment For Autosomal dominant polycystic kidney disease

Nov 02, 2015: Kadmon to Present Clinical Data on Tesevatinib for the Treatment of Polycystic Kidney Disease at ASN's Kidney Week 2015

May 28, 2015: Otsuka's JINARC the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease

Apr 14, 2015: DiscoveryBioMed is developing a novel and unprecedented "dual action" small molecule monotherapy for all cystic fibrosis (CF) patients and for other chronic larger market or rare lung and vascular diseases

Feb 27, 2015: CHMP Recommends JINARC (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease

Feb 26, 2015: First-Ever Treatment Approved in Canada for Adults Living with ADPKD, a Life-Threatening Kidney Disease

Sep 15, 2014: DiscoveryBioMed Awarded A Dual SBIR Awards For Drug Discovery, Validation, Optimization And Development For Autosomal Dominant Polycystic Kidney Disease, The Leading Genetic Cause Of Dialysis And Transplantation Worldwide

Jun 19, 2014: Kadmon Corporation Initiates Phase 2a Portion of KD020 Study in Autosomal Dominant Polycystic Kidney Disease

Jun 11, 2014: Otsuka Pharmaceutical Initiates Phase 3 Clinical Trial Of Tolvaptan In Patients With Autosomal Dominant Polycystic Kidney Disease

May 23, 2014: Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease, an Orphan Disease

Mar 24, 2014: Otsuka Pharmaceutical's Samsca Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Polycystic Kidney Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Polycystic Kidney Disease, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Polycystic Kidney Disease-Pipeline by 3SBio Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Angion Biomedica Corp, H1 2017

Polycystic Kidney Disease-Pipeline by Aptevo Therapeutics Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Polycystic Kidney Disease-Pipeline by DiscoveryBiomed Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Endocyte Inc, H1 2017

Polycystic Kidney Disease-Pipeline by IC-MedTech Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Ipsen SA, H1 2017

Polycystic Kidney Disease-Pipeline by Kadmon Corp LLC, H1 2017

Polycystic Kidney Disease-Pipeline by ManRos Therapeutics, H1 2017

Polycystic Kidney Disease-Pipeline by Metabolic Solutions Development Company LLC, H1 2017

Polycystic Kidney Disease-Pipeline by Mironid Ltd, H1 2017

Polycystic Kidney Disease-Pipeline by NovaTarg Therapeutics Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Otsuka Holdings Co Ltd, H1 2017

Polycystic Kidney Disease-Pipeline by Q BioMed Inc, H1 2017

Polycystic Kidney Disease-Pipeline by Regulus Therapeutics Inc, H1 2017

Polycystic Kidney Disease-Pipeline by XORTX Pharma Corp, H1 2017

Polycystic Kidney Disease-Dormant Projects, H1 2017

Polycystic Kidney Disease-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc, Angion Biomedica Corp, Aptevo Therapeutics Inc, Conatus Pharmaceuticals Inc, DiscoveryBiomed Inc, Endocyte Inc, IC-MedTech Inc, Ipsen SA, Kadmon Corp LLC, ManRos Therapeutics, Metabolic Solutions Development Company LLC, Mironid Ltd, NovaTarg Therapeutics Inc, Otsuka Holdings Co Ltd, Q BioMed Inc, Regulus Therapeutics Inc, XORTX Pharma Corp

select a license

Single User License
USD 2000 INR 129140
Site License
USD 4000 INR 258280
Corporate User License
USD 6000 INR 387420

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com